• Daiichi Sankyo, partnered with AstraZeneca, secured US FDA clearance for Datroway as a first-line treatment for unresectable or metastatic triple-negative breast cancer in patients not eligible for PD-1/PD-L1 inhibitors.
• The TROPION-Breast02 phase 3 trial showed median overall survival of 23.7 months for Datroway versus 18.7 months for chemotherapy.
• The application was reviewed under FDA Project Orbis; regulatory reviews are continuing in Australia, Canada, Singapore, Switzerland.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605220930BIZWIRE_USPR_____20260518_BW016980) on May 22, 2026, and is solely responsible for the information contained therein.